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effect could thus be explained by the predominance of H1N1pdm09 in younger age groups. Our 
results are limited because of the small numbers. This clearly upholds the convenience of networking 
and data pooling between sites applying similar protocols. This study was funded by a grant from 
Sanofi Pasteur. Valencia Hospital Network for the study of Influenza & RVD is a member of the Global 
Influenza Hospital-based Surveillance Network. 
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G Freeman1*, R Pereira1,2, V Fang1, S Ng1, D Ip1, G Leung1, M Peiris1,2, B Cowling1 
1School of Public Health and 2Centre for Influenza Research, Li Ka Shing Faculty of Medicine, The 
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Background: Annual receipt of trivalent inactivated influenza (TIV) vaccination is recommended for 
school-age children in some countries. However, there is little data on the variability of the 
immunogenicity of influenza vaccination in children and how this is affected by their age and recent 
influenza vaccination history. Materials and Methods: We used data on children in a Hong Kong 
community-based study who were randomized to receive TIV before the 2009-2010 influenza season. 
Antibody titers against seasonal and pandemic A(H1N1), seasonal A(H3N2), and two B influenza 
viruses (B/Brisbane and B/Florida) were measured by hemagglutination inhibition immediately before 
and 1 month after vaccination (Cowling et al. Clin Infect Dis. 2012). Multivariate regression models 
were fitted in a Bayesian framework to characterize the distribution of changes in antibody titers 
following vaccination and update previous findings by considering the correlation between virus 
strains (Ng et al. Pediatr Infect Dis J. 2013). Results: In 452 subjects, statistically significant rises in 
the geometric means of all antibody titers were observed, with those against the virus strains included 
in the TIV rising by geometric means of 7.95 to 13.36; those against pandemic A(H1N1) and B/Florida 
rose by 1.47 and 4.21, respectively. Geometric standard deviations were between 3.76 and 8.41 
around the geometric means, with pandemic A(H1N1) showing the least variability in rises. The most 
closely correlated titer increases were those for the two influenza B viruses, while increases in 
pandemic A(H1N1) titers were unrelated to any other titer. Being vaccinated in either of the two 
previous years significantly reduced the increase in seasonal A(H1N1) and A(H3N2) antibody titers, 
while among children not vaccinated in the previous 2 years, those aged > 9 years experienced 
significantly higher increases in the influenza B titers than those aged 6-8 years. Conclusions: 
Increases in antibody titers following vaccination can vary depending on age and vaccination history. 
Results from our study suggest that humoral antibody response to TIV may be lower in children 
receiving repeated vaccination, but receipt of TIV induced seroprotection in most subjects. 
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JY Noh1, JK Park1, DH Lee1, CH Cho2, SS Yuk1, TO Erdene-Ochir1, JH Kwon1, BY Kim1, SW Choi1, 
BS Shim1, MK Song1, JB Lee1, SY Park1, IS Choi1, CS Song1* 
1Avian Disease Laboratory, College of Veterinary Medicine, Konkuk University, Seoul, Republic of 
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Background: Avian influenza virus (AIV) subtype H9N2 has become established in multiple avian 
species across large geographical areas, including Asia, the Middle East, and Africa, causing serious 
economic losses in the poultry industry. To control H9N2 infections in poultry, an oil-based inactivated 
H9N2 vaccine was used in the chicken industry to prevent H9N2 infection in several Asian countries. 
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